CALIFON, NJ - September 15, 2011 - PediatRx Inc. (“PediatRx”) (OTCBB:
PEDX), a hospital specialty company with a current focus on oncology supportive
care, today announced the appointment of Paul J. Richardson to its Board of Directors.
As a pharmaceutical senior executive with more than 30 years of experience in US
and global commercialization, product and business development, and organizational
leadership, Mr. Richardson brings significant expertise in sales management, business
development, licensing, acquisition, commercialization and strategic marketing to
PediatRx.
“We are privileged to welcome a pharmaceutical executive of Paul’s caliber to our
Board. His track record of success coupled with his experience and insight should
contribute significantly to the oversight and operations of PediatRx,” said Dr.
Cameron Durrant, founder of PediatRx.
“PediatRx is doing important work in the field of oncology supportive care and has
a number of opportunities upon which to capitalize going forward,” said Mr. Richardson.
“I am excited to be working with both the Board and the executive team as we move
the company to the next level.”
Mr. Richardson most recently held the position of Regional President of Pfizer’s
North America Specialty Care business unit with direct accountability for the delivery,
in 2010, of over $4.5 billion of annual revenue and associated profitability targets.
He has also held other senior roles within Pfizer and Pfizer heritage companies
during his career. Mr. Richardson holds a BSc (honors) in Physiology from the University
of Leeds, United Kingdom.
About PediatRx
PediatRx, Inc. (www.pediatrx.com) is a hospital
specialty pharmaceutical company which focuses on treatments for patients suffering
from serious conditions requiring hospitalization. PediatRx trades on the OTCBB
under the ticker symbol PEDX.
Futher Information
PediatRx Inc.
Research & Business Development
E-mail: info@pediatrx.com
Shareholder Relations
+1 908-975-0753
E-mail: ir@pediatrx.com
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements
are projections of events, revenues, income, future economics, research, development,
reformulation, product performance or management's plans and objectives for future
operations. In some cases you can identify forward-looking statements by the use
of terminology such as "may", "should", "anticipates", "believes", "expects", "intends",
"forecasts", "plans", "future", "strategy", or words of similar meaning. Forward-looking
statements in this press release include the company’s expectation that Mr. Richardson’s
track record of success and experience should contribute significantly to the oversight
and operations of the company and Mr. Richardson’s belief that the company has a
number of opportunities upon which to capitalize going forward. While these forward-looking
statements and any assumptions upon which they are based are made in good faith
and reflect current judgment regarding the direction of the business operations
of PediatRx, actual results will almost always vary, sometimes materially, from
any estimates, predictions, projections, assumptions or other future performance
suggested in this press release. These statements are predictions and involve known
and unknown risks, uncertainties and other factors, including the risk that PediatRx
cannot execute its business plan for lack of capital or other resources, distribution,
partnering or licensing/acquisition opportunities, as well as the risks described
in the periodic disclosure documents filed on EDGAR by PediatRx, copies of which
are also available on the company’s website. Any of these risks could cause PediatRx
or its industry's actual results, levels of activity, performance or achievements
to be materially different from those expressed or implied by the forward-looking
statements in this press release. Except as required by applicable law, including
the securities laws of the United States, PediatRx does not intend to update any
of the forward-looking statements to conform these statements to actual results.